Corneal and external disordersFungal keratitisSrinivasan, M Author Information Aravind Eye Care System, Tamil Nadu, India Supported by Aravind Medical Research Foundation, Aravind Eye Care System, Madurai, India. Correspondence to M. Srinivasan, Cornea Service, Aravind Eye Care System, 1 Anna Nagar, Madurai, Tamil Nadu, India 625 020 Tel: 91 0452 5356100; fax: 91 0452 2530984; e-mail: [email protected] Current Opinion in Ophthalmology: August 2004 - Volume 15 - Issue 4 - p 321-327 Buy Abstract Purpose of review Throughout the world, fungal keratitis is a leading cause of ocular morbidity. The purpose of this review is to discuss the recently published literature in relation to the epidemiology, etiology, diagnosis, and therapy of fungal keratitis. Recent findings Globally, the incidence of keratomycoses and systemic mycoses is rising. Current therapies are often ineffective. Ongoing research toward rapid diagnosis and specific drug therapy could minimize the morbidity caused by this preventable disease. New antifungal drugs, including voriconazole, have been applied recently for the treatment of keratomycosis. Summary The incidence of fungal keratitis is on the rise in the densely populated continents of Asia and Africa. Filamentous fungi are the most frequently reported pathogens. Polyene antifungal antibiotics, the first-line therapy in fungal keratitis, are not effective in severe keratomycosis. Imidazole derivatives such as voriconazole and echinocandin may be the better choice in the future. © 2004 Lippincott Williams & Wilkins, Inc.